Which Breast Cancer Risk Models Are Most Accurate?


Researchers conducted a validation study of four breast cancer risk models currently in use.

Breast cancer risk models that incorporate multigenerational family history, such as the BOADICEA and IBIS models, fare better at predicting risk than those that do not, according to a new study.

“Models of breast cancer risk based on established risk factors are used to inform decisions about primary prevention,” wrote study authors led by Mary Beth Terry, PhD, of the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center in New York. “Unlike many cardiovascular models, there are few prospective, independent validations of models for estimation of cancer risk.”

A number of breast cancer risk models are currently in use, so researchers conducted a validation study of four of these models: the International Breast Cancer Intervention Study model (IBIS); the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm model (BOADICEA); the BRCAPRO model; and the Breast Cancer Risk Assessment Tool (BCRAT, also referred to as the Gail model). They used data from the 18,856 women included in the Breast Cancer Prospective Family Study Cohort; the results were published in Lancet Oncology.

After a total median follow-up period of 11.1 years, 619 of 15,732 included women were diagnosed with breast cancer (4%). Both the IBIS and BOADICEA models were well calibrated, with a ratio of expected cases to observed cases of 1.03 and 1.05, respectively. Meanwhile, the BRCAPRO and BCRAT models underestimated the risk, with ratios of 0.59 and 0.79, respectively. The estimated C-statistics for the IBIS, BOADICEA, BRCAPRO, and BCRAT models were 0.71, 0.70, 0.68, and 0.60, respectively.

In a subanalysis based on BRCA mutation status, the BOADICEA, IBIS, and BCRAT models were similar, with ratios close to 1 for BRCA-negative women, while the ratio of expected to observed cases with the BRCAPRO model was 0.53. In BRCA-positive women, BOADICEA and IBIS again performed best.

“Our results suggest that models that include multigenerational family history, such as BOADICEA and IBIS, have better ability to predict breast cancer risk, even for women at average or below-average risk of breast cancer,” the authors concluded. “Our study shows that even though some pedigree models are well calibrated, they overpredict risk for women in the upper quantiles of familial risk and underpredict risk for those in the lower quantiles.”

In an accompanying editorial, Montserrat García-Closas, MD, DrPH, of the National Cancer Institute, and Nilanjan Chatterjee, PhD, of Johns Hopkins University, wrote that simpler models such as BCRAT are often preferred due to ease of use and speed. This comes at the expense of accuracy, however. “Although differences in measures of risk discrimination … might be small, more comprehensive information about risk factors could substantially improve the ability to identify women at high or low extremes of risk,” they wrote.

They added that user-friendly interfaces for risk assessment that are tailored to specific clinical scenarios could make the use of complicated risk models easier. “Such an approach would also address the challenge of choosing from the available models without a clear understanding of the pros and cons of each one,” they wrote.

Related Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content